Wojciech Jurczak is a consultant and professor of hematology at Jagiellonian University, Cracow, Poland where he leads the lymphoma team since 1992. Most of the his research activity in the first 15 years were related to development of monoclonal antibodies in B cell lymphomas, and practical aspects of stem cell transplantation. At that time radio-immunotherapy with Y90 labeled Ibritumomab tiuxetan was investigated, especially as consolidation of MCL and DLBCL patients, either in mono-therapy, or as an element of Z-BEAM conditioned ASCT. In the last decade, establishing MCM, a private research facility, allowed the lymphoma team to take part in over 50 clinical trials, including registration studies for Ibrutinib, Idelalisib, Belinostat, Lenalidomide, ABT199 and Rituximab biosymilars. Being a member of ASH, ASCO, PLRG and EMCLN, he co-authored papers published in NEJM, Blood, JCO, The Lancet, Lancet Oncology, Annals of Oncology etc.